DaVita Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensiv...
Latest News
3 days ago · zacks.com
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/YDVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.
3 days ago · marketbeat.com
What DaVita (DVA) Said on Its Q3 Earnings CallDaVita NYSE: DVA reported third-quarter adjusted operating income of $561 million, adjusted earnings per share of $3.82 and free cash flow of $276 million, while narrowing its full-year 2026 outlook. The kidney-care provider said its Integrated Kidney Care business outperformed expectations, though higher technology spending continued to weigh on U.S. dialysis results.
3 days ago · seekingalpha.com
DaVita Inc. (DVA) Q3 2026 Earnings Call TranscriptDaVita Inc. (DVA) Q3 2026 Earnings Call Transcript
3 days ago · zacks.com
DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue EstimatesDaVita HealthCare (DVA) came out with quarterly earnings of $3.82 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $2.51 per share a year ago.
3 days ago · benzinga.com
DaVita Q3 2026 Earnings Call TranscriptDaVita (NYSE:DVA) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
3 days ago · prnewswire.com
DaVita Inc. 3rd Quarter 2026 ResultsDENVER, Oct. 29, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter ended September 30, 2026: Consolidated revenues were $3.578 billion.
6 days ago · zacks.com
Will DaVita's Q3 Earnings Reflect Improving Treatment Growth Trends?DVA's Q3 2026 earnings are expected to rise on improving treatment volumes and cost discipline, but reimbursement pressures could weigh on profitability.
6 days ago · prnewswire.com
DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health RisksNearly 1,000 people screened in Houston and Los Angeles, with a majority showing signs of elevated chronic disease risk DENVER, Oct. 27, 2026 /PRNewswire/ -- Millions of Americans are living with chronic disease and don't know it. The risks are often interconnected: High blood pressure and diabetes can increase the risk of kidney disease, while chronic kidney disease (CKD) often progresses without symptoms.
10 days ago · zacks.com
DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to KnowDaVita HealthCare (DVA) closed at $183.64 in the latest trading session, marking a -1.32% move from the prior day.
11 days ago · zacks.com
DaVita Stock Gains 55.6% Year to Date: What's Behind the Rally?DaVita's 55.6% stock rally reflects stronger operating execution, improving treatment volumes and value-based kidney care gains despite reimbursement pressures.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove DVA